argenx NV ADR has seen a significant decline of 13.7% this week, driven by recent trial news.
This week, argenx NV ADR experienced a notable decline of 13.7%, closing at US$826.91. The drop in share price follows the company's announcement of halting a late-stage study for an autoimmune disease, raising concerns among investors about the company's future prospects. Over the past month, the stock has decreased by 18.46%, and it is down 4.45% year-to-date. The current price is also 13.5% below its 50-day moving average of US$955.51 and 2.9% below its 200-day moving average of US$851.80.
Advertisement
argenx NV ADR
ARGX.US
ARGX.US
argenx NV ADR
WealthAwesomeMarket cap
$51.07B
P/E
30.9x
52W high
$1072.75
52W low
$661.85
1W change
-13.74%
Beta
-0.04
Analyst Price Targets
Based on 25 analysts covering ARGX · as of Oct 14, 2026
Wall Street analysts forecast ARGX stock price to rise 43.6% over the next 12 months.
Consensus
Buy4.48 / 5.00
Avg. Target
C$1152.65
+43.6% Upside
Previously C$1154.43 on Oct 12, 2026
Current Price
C$802.64
Last close
Analyst Breakdown (25 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ARGX's historical volatility
30-Day Vol
41.2%
Annualized
90-Day Vol
46.6%
Annualized
Trend (90d)
-22.2%
Annualized drift
90d Mean
C$741.48
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$781.71 | C$678.10 – C$901.16 |
| 60 trading days | C$761.33 | C$622.65 – C$930.91 |
| 90 trading days | C$741.48 | C$579.61 – C$948.55 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should monitor upcoming developments regarding argenx's clinical trials and market performance.
Volume at 315,145 Shares, Below 20-Day Average
This week's trading volume was 315,145 shares, which is 68% of the 20-day average of 407,502 shares, indicating reduced investor interest.
Bull case
Analysts are optimistic, with an average target of US$1152.65. This suggests that there could be potential upside despite the recent challenges.
Bear case
The halted study and mixed trial results raise concerns about deeper issues within argenx's pipeline, which could affect future growth.
Significant Decline Following Study Halt
Advertisement
This week, argenx NV ADR's stock declined by 13.7%, closing at US$826.91. This drop was triggered by the company's decision to halt a late-stage study focused on an autoimmune disease, raising concerns about its product pipeline and potential revenue streams. This decline marks a significant downturn following a 185% run-up prior to the recent news, prompting questions about the stock's current valuation.
Trading Volume Below Average
The latest trading volume for argenx was 315,145 shares, significantly lower than the 20-day average volume of 407,502 shares. This indicates reduced trading activity and possible investor hesitance following the negative news. This volume represents 68% of the average, suggesting that fewer investors are willing to engage with the stock at this time. The stock's current position in the 52-week range is also noteworthy, trading around 40% of the range between US$661.85 and US$1072.75.
Future Developments to Watch
Looking ahead, investors should keep an eye on any updates regarding argenx's clinical trials and future studies, as these will be critical in determining the company's trajectory. Additionally, the stock's current P/E ratio of 30.95 and a profit margin of 32.3% will be important metrics for analysts evaluating the company's potential amidst these challenges. The average analyst target of US$1152.65 suggests a potential upside of 39.4%, which could be a focal point for investors moving forward.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
